Rifaximin on epigenetics and autophagy in animal model of hepatocellular carcinoma secondary to metabolic-dysfunction associated steatotic liver disease

Table 4 Comparison between animals in the rifaximin-group that developed or not hepatocellular carcinoma

Variables1	Developed HCC (n = 4), median (min–max)	Did not developed HCC (n = 3), median (min–max)	P value
miR-122	2.27 (1.20–4.57)	2.97 (1.51–5.98)	0.571
miR-375	0.42 (0.14–1.76)	0.33 (0.30–0.67)	1.000
miR-26b	1.97 (1.10–3.38)	2.41 (1.97–3.99)	0.571
miR-224	0.46 (0.13–0.85)	0.58 (0.46–0.82)	0.857
miR-34	11.0 (7.17–18.9)	10.0 (8.64–10.5)	0.786
miR-21	2.36 (0.84–3.68)	1.68 (1.00–1.69)	0.700
miR-143	0.76 (0.17–2.53)	0.48 (0.25–1.96)	1.000
miR-155	0.69 (0.06–1.46)	0.13 (0.03–0.36)	0.250
miR-33a	0.88 (0.52–1.86)	1.55 (1.40–1.58)	0.400
Mm2	7.95 (0.58–18.4)	0.71 (0.16–0.92)	0.229
Mm9	24.0 (1.32–28.7)	8.48 (1.73–14.6)	0.400
Afp	6.99 (1.38–19.8)	0.46 (0.29–0.48)	0.057
Tuba1c	4.63 (0.30–7.12)	0.26 (0.25–0.30)	0.057
Aldob	2.32 (0.11–2.69)	0.07 (0.00–0.12)	0.114
Becn1	0.70 (0.67–0.85)	0.74 (0.66–0.76)	1.000
p62/Sqstm1	0.84 (0.54–0.98)	0.72 (0.64–0.79)	0.629
Map1lc3b	0.24 (0.22–0.35)	0.27 (0.21–0.29)	1.000
Ezh2	29.0 (28.0–30.1)	27.5 (27.2–28.0)	0.114
Carm1	0.79 (0.77–1.67)	1.23 (1.08–1.68)	0.400
p62/SQSTM1 protein	1.07 (0.16–2.89)	1.78 (1.19–2.36)	0.355
MAP1LC3B protein	2.00 (0.87–4.78)	2.20 (0.86–3.57)	0.643

¹Variables expressed by median (25^th–75^th percentiles).

P < 0.05 is considered significant.

Aldob: Aldolase B; Afp: Alpha-fetoprotein; Becn-1: Beclin-1; Carm1: Coactivator associated arginine methyltransferase-1; Ezh-2: Enhancer of zeste homolog-2; HCC: Hepatocellular carcinoma; Map1lc3b: Autophagy-related factor LC3A/B; Mmp: Metalloproteinases; p62/Sqstm1: P62/sequestosome-1; RIF: Rifaximin; Tuba1c: Tubulin alpha 1c.